The deal would give GSK the rights to develop the drug for HRD-9821 and 11 preclinical programmes owned by Jiangsu Hengrui ...

Pfizer Inc. (NYSE:PFE) is among the 12 Best Ethical Companies to Invest in 2025. On July 24, 2025, Pfizer Inc. (NYSE:PFE) ...

Pfizer agreed to an upfront payment of US$1.25 billion, US$150 million for mainland rights and a US$100 million equity ...

Moderna has scrapped plans to build an mRNA plant in Japan. Otsuka and Lundbeck's proposal for Rexulti as part of a PTSD ...

As part of the agreement, which was signed in May 2025, 3SBio will receive $1.25bn, along with a $100m equity investment from ...

New capital, maturing pipelines, and a more global R&D mindset are pushing valuations higher, even as competition tightens.

Pfizer Inc. has completed the previously announced global, ex-China, licensing agreement with 3SBio Inc., which grants Pfizer exclusive rights for the development, manufacturing and commercialization ...

Thai F-16 fighter jets struck military sites in neighboring Cambodia as a border dispute between the Southeast Asian nations, stretching back decades, erupted in fresh violence that killed at least ...

Pfizer is on the brink of a major rebound, transitioning focus to oncology and potential blockbuster drugs after a sharp drop in COVID-related revenues. Pfizer’s stock has plummeted over 50% in the ...

Pfizer is positioning for a potential long-term rebound following a steep post-COVID revenue decline and a drop of over 50% ...

AstraZeneca, Pfizer and other multinational drug companies have spent a record amount on medicines developed by Chinese biotechs this year, underscoring how Big Pharma is increasingly reliant on China ...